Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
The expression ICOS on activated T lymphocytes. BALB/c splenocytes were either unstimulated (top panels) or activated by culture for 48 hours in the presence of soluble 145-2C11 mAb (anti-mouse CD3e, Cat. No. 553057, bottom panels). Both sets of cells were stained with either PE-conjugated rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553989, left panels) or PE-conjugated mAb 7E.17G9 (right panels), then FITC-conjugated mAb 53-6.7 (anti-mouse CD8a, Cat. No. 553030/553031). Viable leukocytes were selected by exclusion of propidium iodide. Flow cytometry was performed on a FACSCalibur™ (BD Biosciences, San Jose, CA).
The expression ICOS on activated T lymphocytes. BALB/c splenocytes were either unstimulated (top panels) or activated by culture for 48 hours in the presence of soluble 145-2C11 mAb (anti-mouse CD3e, Cat. No. 553057, bottom panels). Both sets of cells were stained with either PE-conjugated rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553989, left panels) or PE-conjugated mAb 7E.17G9 (right panels), then FITC-conjugated mAb 53-6.7 (anti-mouse CD8a, Cat. No. 553030/553031). Viable leukocytes were selected by exclusion of propidium iodide. Flow cytometry was performed on a FACSCalibur™ (BD Biosciences, San Jose, CA).
The expression ICOS on activated T lymphocytes. BALB/c splenocytes were either unstimulated (top panels) or activated by culture for 48 hours in the presence of soluble 145-2C11 mAb (anti-mouse CD3e, Cat. No. 553057, bottom panels). Both sets of cells were stained with either PE-conjugated rat IgG2b, κ isotype control mAb A95-1 (Cat. No. 553989, left panels) or PE-conjugated mAb 7E.17G9 (right panels), then FITC-conjugated mAb 53-6.7 (anti-mouse CD8a, Cat. No. 553030/553031). Viable leukocytes were selected by exclusion of propidium iodide. Flow cytometry was performed on a FACSCalibur™ (BD Biosciences, San Jose, CA).
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The 7E.17G9 monoclonal antibody specifically binds to CD278, the Inducible Costimulatory molecule (ICOS), a 47-57 kDa homodimeric glycoprotein of the CD28 family of costimulatory molecules. ICOS is expressed on subpopulations of CD4-CD8- and CD4+CD8- (but not CD4-CD8+ or CD4+CD8+) thymocytes, on some T-cell lines, and on small numbers of peripheral leukocytes. It is upregulated on T lymphocytes following activation via the T-cell receptor. The T-cell activation marker H4 is the same molecule as ICOS. ICOS is a costimulatory receptor, and its ligand on antigen-presenting cells has been called B7RP-1, GL50, B7h, B7-H2, or LICOS. There is considerable evidence that the interaction of ICOS with its ligand is involved in the regulation of many, but not all, T-cell-mediated immune responses.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.